ATE361067T1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents
Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungenInfo
- Publication number
- ATE361067T1 ATE361067T1 AT02745640T AT02745640T ATE361067T1 AT E361067 T1 ATE361067 T1 AT E361067T1 AT 02745640 T AT02745640 T AT 02745640T AT 02745640 T AT02745640 T AT 02745640T AT E361067 T1 ATE361067 T1 AT E361067T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- treatment
- neurodegenerative diseases
- inhibitors
- tau aggregation
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 238000004220 aggregation Methods 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 241000276398 Opsanus tau Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000012711 vitamin K3 Nutrition 0.000 abstract 1
- 239000011652 vitamin K3 Substances 0.000 abstract 1
- 229940041603 vitamin k 3 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117326.9A GB0117326D0 (en) | 2001-07-16 | 2001-07-16 | Napthoquinone-type inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361067T1 true ATE361067T1 (de) | 2007-05-15 |
Family
ID=9918593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745640T ATE361067T1 (de) | 2001-07-16 | 2002-07-16 | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7605179B2 (de) |
| EP (1) | EP1408952B1 (de) |
| JP (1) | JP5147157B2 (de) |
| CN (1) | CN1313088C (de) |
| AT (1) | ATE361067T1 (de) |
| AU (1) | AU2002317354B2 (de) |
| CA (1) | CA2451422C (de) |
| DE (1) | DE60219917T2 (de) |
| ES (1) | ES2287292T3 (de) |
| GB (1) | GB0117326D0 (de) |
| SG (1) | SG148846A1 (de) |
| WO (1) | WO2003007933A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| CA2528627A1 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
| WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
| WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| FR2874923B1 (fr) * | 2004-09-07 | 2006-10-27 | Trophos Sa | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
| US7790881B2 (en) | 2004-09-23 | 2010-09-07 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| JP4734602B2 (ja) | 2004-12-21 | 2011-07-27 | Ｄｏｗａエレクトロニクス株式会社 | 保存安定性に優れた窒化鉄系磁性粉末 |
| JP4822312B2 (ja) * | 2005-05-13 | 2011-11-24 | 学校法人慶應義塾 | ナフトキノン誘導体化合物 |
| KR100699945B1 (ko) * | 2005-11-24 | 2007-03-26 | (주) 디지탈바이오텍 | 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
| JP5654748B2 (ja) | 2006-03-29 | 2015-01-14 | ウイスタ・ラボラトリーズ・リミテッドＷｉｓｔａ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｔｄ． | タンパク質凝集の阻害物質 |
| DE602007008550D1 (de) | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| CA2655632A1 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | Inhibitors of a.beta. and synuclein aggregation |
| JP5537151B2 (ja) * | 2007-04-05 | 2014-07-02 | 株式会社Ｊ−オイルミルズ | 精神安定剤および機能性食品 |
| JP2010538611A (ja) * | 2007-09-07 | 2010-12-16 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | タウタンパク質スクリーニングアッセイ |
| EP2060256A1 (de) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen |
| GB0816269D0 (en) * | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
| JP2013529181A (ja) | 2010-03-25 | 2013-07-18 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 神経障害を治療するための組成物および方法 |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| SG187744A1 (en) * | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| AU2011358840B2 (en) | 2011-02-11 | 2017-05-04 | TauRx Therapeutics Management Ltd | Phenothiazine diaminium salts and their use |
| WO2012145169A2 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| EP2764863B1 (de) | 2011-10-03 | 2020-03-11 | National Center for Geriatrics and Gerontology | Tau-aggregationshemmer |
| WO2013115867A1 (en) | 2012-02-05 | 2013-08-08 | Biodesy, Llc | Methods for identifying modulators of ras using nonlinear techniques |
| SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| CA2889197A1 (en) | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| US9907799B2 (en) | 2013-04-02 | 2018-03-06 | The Doshisha | Tau aggregation inhibitor |
| EA039554B1 (ru) | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
| JP6518656B2 (ja) * | 2013-06-13 | 2019-05-22 | バイオデシー， インコーポレイテッド | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
| US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
| EP3237906B8 (de) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion |
| US11628147B2 (en) | 2017-12-19 | 2023-04-18 | Synergia Life Sciences Pvt. Ltd. | Vitamin K2 compositions for the treatment of drug induced neuropathy |
| EP3773530A4 (de) | 2018-03-30 | 2022-03-02 | Kaydence Pharma AS | Schnelle verbesserung von gefässerkrankungen durch verabreichung von vitamin k |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| CN110025624B (zh) * | 2019-05-29 | 2021-04-02 | 济宁医学院附属医院 | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 |
| CN112778092B (zh) * | 2020-12-31 | 2023-03-24 | 玉溪健坤生物药业有限公司 | 一种还原型维生素k2的制备方法及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59175449A (ja) * | 1983-03-26 | 1984-10-04 | Kyushu Kogyo Daigaku | シコニンの製造法 |
| JPS61143334A (ja) * | 1984-12-18 | 1986-07-01 | Mitsui Petrochem Ind Ltd | ５，８−ジヒドロキシ−１，４−ナフトキノン誘導体 |
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| US5763479A (en) * | 1991-02-04 | 1998-06-09 | Ks Biomedix Ltd. | Naphthoquinone derivatives for the treatment of chronic inflammation |
| ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
| EP0778773A1 (de) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Verfahren zur behandlung und/oder vorbeugung von alzheimer'sche krankheit mit phenothiazine und/oder thioxanthene |
| JPH08193026A (ja) * | 1995-01-12 | 1996-07-30 | Teijin Ltd | アミロイドβ蛋白凝集・沈着阻害剤 |
| DE19504003A1 (de) * | 1995-02-08 | 1996-08-14 | Martin Dr Kohlmeier | Verwendungen eines Vitamins der K-Gruppe |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) * | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| KR0180791B1 (ko) * | 1995-07-24 | 1999-05-15 | 김용옥 | 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도 |
| JP3809014B2 (ja) * | 1998-05-22 | 2006-08-16 | 花王株式会社 | 養毛・育毛剤 |
| US20020040011A1 (en) * | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| US20020016372A1 (en) * | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US6953974B2 (en) | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| EP1799662B1 (de) | 2004-09-23 | 2013-04-17 | Wista Laboratories Ltd. | Verfahren zur chemischen synthese und aufreinigung von diaminophenothiaziniumverbindungen einschliesslich methylthioniniumchlorid (mtc) |
-
2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
-
2002
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en not_active Ceased
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60219917D1 (de) | 2007-06-14 |
| JP5147157B2 (ja) | 2013-02-20 |
| GB0117326D0 (en) | 2001-09-05 |
| CN1553800A (zh) | 2004-12-08 |
| JP2004534854A (ja) | 2004-11-18 |
| CA2451422A1 (en) | 2003-01-30 |
| WO2003007933A1 (en) | 2003-01-30 |
| DE60219917T2 (de) | 2008-01-17 |
| HK1063012A1 (en) | 2004-12-10 |
| CA2451422C (en) | 2010-10-19 |
| SG148846A1 (en) | 2009-01-29 |
| US7605179B2 (en) | 2009-10-20 |
| AU2002317354B2 (en) | 2007-07-19 |
| EP1408952B1 (de) | 2007-05-02 |
| US20050107472A1 (en) | 2005-05-19 |
| ES2287292T3 (es) | 2007-12-16 |
| EP1408952A1 (de) | 2004-04-21 |
| CN1313088C (zh) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DK1465626T3 (da) | Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf | |
| DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO961326D0 (no) | Inhibitorer av | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE480235T1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
| ATE553114T1 (de) | Verbindungen zur verminderung der aggregation von amyloid-beta-peptid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1408952 Country of ref document: EP |